We have a deep understanding of 5-HT2B receptor biology and fibrosis.
Fibrotic disorders collectively affect millions of patients but in many areas have limited, if any, treatment options.
Fibrosis is the deterioration of healthy tissue and development of fibrous connective tissue caused by fibroblasts and macrophages. Fibrosis can be organ specific or systemic and leads to organ dysfunction, morbidity and mortality.
We are developing our first-in class, orally bioavailable, peripherally acting 5-HT2B receptor antagonists to prevent and reverse fibrosis.
AnaMar’s 5-HT2B receptor antagonists are protected worldwide by patents in territories of commercial relevance. AnaMar’s patent strategy is global, and our patent portfolio includes a wide range of additional 5-HT2B receptor antagonists.